Tibsovo® (ivosidenib) – New indication
August 27, 2021 - Servier Pharmaceuticals announced the FDA approval of Tibsovo (ivosidenib), for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Top